Developer docs
API playgroundTry for free, no card

Search company profiles

Valentech

Full company profile

uuid000c8j9

Namestring
Valentech
Legal namestring
Valentech Pharma
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Valentech Pharma is a privately held pharmaceutical licensing, import, and commercialization company headquartered in Bogotá, Colombia, founded in 2011. The company specializes in rare and orphan diseases across eight high-specialty therapeutic areas: rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics. It operates in four Latin American countries — Colombia (home market), Ecuador (since 2022), Peru (since 2024), and Panama (since 2025) — through dedicated offices in Bogotá, Quito, Lima, and Panama City.

Valentech's business model is a one-stop-shop distribution platform: it signs licensing agreements with international pharmaceutical companies (over 10 named partners including BioMarin, Daewoong, Sarepta, Orphalan, Clinuvel, Esteve, Theravia, Biocodex, and Kamada), handles local regulatory registration and importation, then commercializes the products through its own field sales infrastructure targeting specialty physicians, hospitals, and rare disease patients. Revenue is generated through licensing royalties and distribution margins on pharmaceutical product sales; pricing is negotiated on a per-contract basis and not publicly disclosed.

Valentech has built a digital ecosystem supporting its core distribution business: Valentech Access (a platform managing compassionate use and expanded access programs), Valentech Academy/Universidad Valentech (a Moodle-based e-learning platform for medical professionals), and clinical decision-support tools including the Hipercolesterolemia Familiar calculator and the Pheburane dosing calculator. The company holds compliance certifications (ISO 9001, ISO 27001, SOC 2, GDPR, CCPA) and formal Colombian regulatory policies (SAGRILAFT, PTEE), and operates a Patient Support Program with dedicated pharmacovigilance infrastructure. The August 2025 $24.5 million agreement with Daewoong Pharmaceutical for Nabota distribution represents its largest disclosed commercial contract and signals expansion beyond orphan drugs into aesthetics and therapeutics.

Short descriptiontext

Valentech Pharma is a Colombian pharmaceutical company that licenses, registers, and commercializes rare disease and high-specialty therapies across four Latin American countries for global pharma partners including BioMarin, Daewoong, and Sarepta.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBogotá, Colombia
HQ citystring
Bogotá
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, pharmaceutical licensing, specialty drug distribution, orphan disease therapies, medical education platforms
Industry1 code
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceutical Distribution
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Licensing and Distribution
TypeLicensing Royalties
Description

Valentech Pharma generates revenue through licensing agreements with international pharmaceutical companies to register, import, and commercialize innovative therapies for rare and high-specialty diseases in Latin American markets. The company also signed a $24.5 million export deal with Daewoong Pharmaceutical to distribute Nabota (botulinum toxin) in Colombia, expanding into the Latin American aesthetics and therapeutics market.

valentechforlife.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Valentech Academy
Description

Online learning platform providing practical and complete medical education for healthcare professionals.

valentechforlife.com
+2 more records
Core offering1 text field

Valentech Pharma is a pharmaceutical licensing, import, and commercialization company that registers, imports, and distributes innovative therapies for rare and orphan diseases in Colombia, Ecuador, Peru, and Panama. It partners with international pharmaceutical companies to bring high-specialty treatments to Latin America in therapeutic areas including rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Valentech Pharma is a pharmaceutical distribution company specializing in orphan/rare diseases and high-specialty medications across Latin America. The company operates a portfolio of platforms including Valentech Access (digital medication access management), Valentech Academy/Universidad Valentech (e-learning for medical professionals), and clinical tools such as the Hipercolesterolemia Familiar Calculator and Pheburane Calculator. They license, register, import, and commercialize innovative therapies from global pharmaceutical partners, focusing on therapeutic areas including rare cancers, endocrinology, congenital metabolism errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics. Their Patient Support Program provides accompaniment services to patients and families affected by rare diseases.

Product and service7 records
1Licensing, Import, and Commercialization of Rare Disease Therapies
CategoryPharmaceutical Licensing and Distribution
Description

Core service through which Valentech signs licensing and distribution agreements with international pharmaceutical companies to register, import, and commercialize innovative therapies for rare and high-specialty diseases in Latin American markets, serving patients with rare cancers, endocrinology disorders, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatric conditions.

2Valentech Access
CategoryDigital Health Platform
Description

Digital platform that manages transparently, securely, and efficiently the access of patients to special medications in compassionate use situations or under early/expanded access programs. Used by healthcare providers and patients seeking access to innovative therapies.

3Valentech Academy (Universidad Valentech)
CategoryMedical Education Platform
Description

E-learning platform providing practical and comprehensive medical education for healthcare professionals on rare diseases and specialized treatments, available through the Moodle-based portal at university.valentechforlife.com.

4Hipercolesterolemia Familiar Calculator (HFHO)
CategoryClinical Decision Support Tool
Description

Online diagnostic tool that enables physicians to calculate familial hypercholesterolemia diagnostic criteria for patients, supporting clinical decision-making for this rare lipid disorder.

5Pheburane Dosing Calculator
CategoryClinical Decision Support Tool
Description

Dosing calculator tool (version 3.0) that supports physicians in determining correct Pheburane (sodium phenylbutyrate) dosing for patients with urea cycle disorders.

6Patient Support Program
CategoryPatient Support Services
Description

Service program providing information, guidance, and accompaniment to patients with rare diseases and their caregivers across Latin America, with dedicated contact channels and email support (programapacientes@valentechforlife.com).

7Pharmacovigilance Service (Farmacovigilancia)
CategoryRegulatory and Safety Services
Description

Adverse event reporting and ongoing drug safety monitoring service provided to pharmaceutical partners and regulatory authorities across Valentech's commercial markets.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-26
Description

Daewoong Pharmaceutical signed a $24.5 million export deal with Valentech Pharma to sell its botulinum toxin Nabota in Colombia. This agreement aims to expand Nabota's presence in Latin America's fast-growing aesthetics market, following similar market entries in Brazil, Mexico, and Argentina. Valentech serves as the local distribution and commercialization partner for Daewoong's products in Colombia.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioMarin is listed as one of Valentech Pharma's key pharmaceutical partners. Valentech represents and commercializes BioMarin's innovative rare disease therapies in Latin American markets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sarepta Therapeutics is listed as one of Valentech Pharma's key pharmaceutical partners. Valentech represents and commercializes Sarepta's rare disease therapies including treatments for Duchenne muscular dystrophy in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Orphalan is listed as a key partner of Valentech Pharma, representing the company's portfolio of treatments for rare diseases in Latin America.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Esteve is listed as one of Valentech Pharma's pharmaceutical partners, representing treatments for rare diseases in Latin America.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Theravia is listed as a pharmaceutical partner of Valentech Pharma, collaborating on rare disease treatments in the Latin American market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinuvel is listed as a pharmaceutical partner of Valentech Pharma, representing treatments for rare diseases in Latin America.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biocodex is listed as a pharmaceutical partner of Valentech Pharma, collaborating on rare disease treatments in the Latin American market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Kamada is listed as a pharmaceutical partner of Valentech Pharma, representing treatments for rare diseases in Latin America.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Eurofarma
TypeBroad incumbent
Description

Largest multinational pharmaceutical company in Latin America, headquartered in Brazil, with a broad portfolio including specialty and rare disease products. Acts as a broad incumbent with overlapping distribution and commercialization capabilities across LatAm.

TypeBroad incumbent
Description

Global specialty pharmaceutical group with a dedicated rare disease business commercializing treatments for metabolic, endocrine, and ultra-rare conditions worldwide. Comparable in therapeutic focus and in operating a specialty/rare-disease distribution model, but at a global rather than LatAm-localized scale.

TypeDirect peer
Description

Latin American pharmaceutical company with presence in 18+ countries covering branded generics, specialty, and rare disease products. Comparable as a multi-country LatAm commercialization partner for global pharma, with overlap in therapeutic categories such as gastro/hepato and endocrinology.

4Raffo Laboratorios
TypeRegional player
Description

Argentine pharmaceutical company with branded specialty, oncology, and rare disease products distributed across several LatAm countries. Comparable regional specialty pharmaceutical distributor with overlapping therapeutic categories, though headquartered and primarily operating in the Southern Cone.

TypeBroad incumbent
Description

Global specialty biopharma focused on rare diseases (haematology, immunology, specialty care). Comparable therapeutic-area focus and partner-driven commercialization model, with growing LatAm presence. Larger and more globalized than Valentech.

TypeRegional player
Description

Largest Brazilian pharmaceutical company by market cap, with branded prescription, specialty, and consumer health products across LatAm. Comparable as a scaled LatAm pharmaceutical commercialization platform, though primarily Brazil-focused rather than Andean-region focused like Valentech.

TypeBroad incumbent
Description

Global leader in rare disease therapeutics (now part of AstraZeneca), commercializing treatments across haematology, nephrology, neurology, and metabolic rare diseases. Comparable in therapeutic focus areas where Valentech operates and in expanding access to LatAm via local partnerships.

TypeDirect peer
Description

Latin American specialty pharmaceutical company focused on rare diseases, specialty therapies, and biologics across multiple LatAm countries. Operates a very similar licensing, registration, importation, and commercialization model with global pharma partners, making it the closest functional peer to Valentech.

TypeDirect peer
Description

Specialty pharmaceutical distributor headquartered in LatAm (acquired by Knight Therapeutics), commercializing innovative therapies including rare disease products across the region. Highly comparable model of licensing and distributing partner pharma products across multiple LatAm markets.

TypeBroad incumbent
Description

Global rare disease franchise (formerly Genzyme) commercializing therapies for rare and specialty conditions with established LatAm operations. Overlaps with Valentech on therapeutic areas such as rare metabolic, hematology, and neuropediatric conditions, but at a much larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valentech

Specialty Pharmaceutical Distributionvalentechforlife.com

Valentech Pharma is a Colombian pharmaceutical company that licenses, registers, and commercializes rare disease and high-specialty therapies across four Latin American countries for global pharma partners including BioMarin, Daewoong, and Sarepta.

What Valentech does

Valentech Pharma is a privately held pharmaceutical licensing, import, and commercialization company headquartered in Bogotá, Colombia, founded in 2011. The company specializes in rare and orphan diseases across eight high-specialty therapeutic areas: rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics. It operates in four Latin American countries — Colombia (home market), Ecuador (since 2022), Peru (since 2024), and Panama (since 2025) — through dedicated offices in Bogotá, Quito, Lima, and Panama City.

Valentech's business model is a one-stop-shop distribution platform: it signs licensing agreements with international pharmaceutical companies (over 10 named partners including BioMarin, Daewoong, Sarepta, Orphalan, Clinuvel, Esteve, Theravia, Biocodex, and Kamada), handles local regulatory registration and importation, then commercializes the products through its own field sales infrastructure targeting specialty physicians, hospitals, and rare disease patients. Revenue is generated through licensing royalties and distribution margins on pharmaceutical product sales; pricing is negotiated on a per-contract basis and not publicly disclosed.

Valentech has built a digital ecosystem supporting its core distribution business: Valentech Access (a platform managing compassionate use and expanded access programs), Valentech Academy/Universidad Valentech (a Moodle-based e-learning platform for medical professionals), and clinical decision-support tools including the Hipercolesterolemia Familiar calculator and the Pheburane dosing calculator. The company holds compliance certifications (ISO 9001, ISO 27001, SOC 2, GDPR, CCPA) and formal Colombian regulatory policies (SAGRILAFT, PTEE), and operates a Patient Support Program with dedicated pharmacovigilance infrastructure. The August 2025 $24.5 million agreement with Daewoong Pharmaceutical for Nabota distribution represents its largest disclosed commercial contract and signals expansion beyond orphan drugs into aesthetics and therapeutics.

Valentech firmographics

Firmographics
Name
Valentech
Legal name
Valentech Pharma
Website
https://valentechforlife.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Valentech Pharma is a Colombian pharmaceutical company that licenses, registers, and commercializes rare disease and high-specialty therapies across four Latin American countries for global pharma partners including BioMarin, Daewoong, and Sarepta.
Ownership category
akta.pro rank

Valentech industry classification

Industry
Product category
Specialty Pharmaceutical Distribution
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • Rare disease therapeutics
  • Pharmaceutical licensing
  • Specialty drug distribution
  • Orphan disease therapies
  • Medical education platforms

Where Valentech is headquartered

Location

Headquarters

HQ city
Bogotá
HQ country
Colombia
HQ region
Latin America

Offices4 records

Markets served

Valentech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Licensing and Distribution: Valentech Pharma generates revenue through licensing agreements with international pharmaceutical companies to register, import, and commercialize innovative therapies for rare and high-specialty diseases in Latin American markets. The company also signed a $24.5 million export deal with Daewoong Pharmaceutical to distribute Nabota (botulinum toxin) in Colombia, expanding into the Latin American aesthetics and therapeutics market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Valentech product offering

Product offering

Core offering

Valentech Pharma is a pharmaceutical licensing, import, and commercialization company that registers, imports, and distributes innovative therapies for rare and orphan diseases in Colombia, Ecuador, Peru, and Panama. It partners with international pharmaceutical companies to bring high-specialty treatments to Latin America in therapeutic areas including rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics.

Product overview

Valentech Pharma is a pharmaceutical distribution company specializing in orphan/rare diseases and high-specialty medications across Latin America. The company operates a portfolio of platforms including Valentech Access (digital medication access management), Valentech Academy/Universidad Valentech (e-learning for medical professionals), and clinical tools such as the Hipercolesterolemia Familiar Calculator and Pheburane Calculator. They license, register, import, and commercialize innovative therapies from global pharmaceutical partners, focusing on therapeutic areas including rare cancers, endocrinology, congenital metabolism errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics. Their Patient Support Program provides accompaniment services to patients and families affected by rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • Valentech Academy: Online learning platform providing practical and complete medical education for healthcare professionals.
  • Valentech Access
  • Universidad Valentech

Products and services

  • Licensing, Import, and Commercialization of Rare Disease Therapies Core service through which Valentech signs licensing and distribution agreements with international pharmaceutical companies to register, import, and commercialize innovative therapies for rare and high-specialty diseases in Latin American markets, serving patients with rare cancers, endocrinology disorders, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatric conditions.
  • Valentech Access Digital platform that manages transparently, securely, and efficiently the access of patients to special medications in compassionate use situations or under early/expanded access programs. Used by healthcare providers and patients seeking access to innovative therapies.
  • Valentech Academy (Universidad Valentech) E-learning platform providing practical and comprehensive medical education for healthcare professionals on rare diseases and specialized treatments, available through the Moodle-based portal at university.valentechforlife.com.
  • Hipercolesterolemia Familiar Calculator (HFHO) Online diagnostic tool that enables physicians to calculate familial hypercholesterolemia diagnostic criteria for patients, supporting clinical decision-making for this rare lipid disorder.
  • Pheburane Dosing Calculator Dosing calculator tool (version 3.0) that supports physicians in determining correct Pheburane (sodium phenylbutyrate) dosing for patients with urea cycle disorders.
  • Patient Support Program Service program providing information, guidance, and accompaniment to patients with rare diseases and their caregivers across Latin America, with dedicated contact channels and email support (programapacientes@valentechforlife.com).
  • Pharmacovigilance Service (Farmacovigilancia) Adverse event reporting and ongoing drug safety monitoring service provided to pharmaceutical partners and regulatory authorities across Valentech's commercial markets.

Companies that use Valentech

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Valentech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Valentech partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Daewoong PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 26 August 2025Daewoong Pharmaceutical signed a $24.5 million export deal with Valentech Pharma to sell its botulinum toxin Nabota in Colombia. This agreement aims to expand Nabota's presence in Latin America's fast-growing aesthetics market, following similar market entries in Brazil, Mexico, and Argentina. Valentech serves as the local distribution and commercialization partner for Daewoong's products in Colombia.
  • BioMarincoreStrategic or Co-development PartnerBioMarin is listed as one of Valentech Pharma's key pharmaceutical partners. Valentech represents and commercializes BioMarin's innovative rare disease therapies in Latin American markets.
  • Sarepta TherapeuticscoreStrategic or Co-development PartnerSarepta Therapeutics is listed as one of Valentech Pharma's key pharmaceutical partners. Valentech represents and commercializes Sarepta's rare disease therapies including treatments for Duchenne muscular dystrophy in Latin America.
  • OrphalancoreStrategic or Co-development PartnerOrphalan is listed as a key partner of Valentech Pharma, representing the company's portfolio of treatments for rare diseases in Latin America.
  • EsteveminorStrategic or Co-development PartnerEsteve is listed as one of Valentech Pharma's pharmaceutical partners, representing treatments for rare diseases in Latin America.
  • TheraviaminorStrategic or Co-development PartnerTheravia is listed as a pharmaceutical partner of Valentech Pharma, collaborating on rare disease treatments in the Latin American market.
  • ClinuvelminorStrategic or Co-development PartnerClinuvel is listed as a pharmaceutical partner of Valentech Pharma, representing treatments for rare diseases in Latin America.
  • BiocodexminorStrategic or Co-development PartnerBiocodex is listed as a pharmaceutical partner of Valentech Pharma, collaborating on rare disease treatments in the Latin American market.
  • KamadaminorStrategic or Co-development PartnerKamada is listed as a pharmaceutical partner of Valentech Pharma, representing treatments for rare diseases in Latin America.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Valentech competitors and assessment

Company assessment

Broad incumbents

  • Eurofarma: Largest multinational pharmaceutical company in Latin America, headquartered in Brazil, with a broad portfolio including specialty and rare disease products. Acts as a broad incumbent with overlapping distribution and commercialization capabilities across LatAm.
  • Recordati Rare Diseases: Global specialty pharmaceutical group with a dedicated rare disease business commercializing treatments for metabolic, endocrine, and ultra-rare conditions worldwide. Comparable in therapeutic focus and in operating a specialty/rare-disease distribution model, but at a global rather than LatAm-localized scale.
  • Swedish Orphan Biovitrum (Sobi): Global specialty biopharma focused on rare diseases (haematology, immunology, specialty care). Comparable therapeutic-area focus and partner-driven commercialization model, with growing LatAm presence. Larger and more globalized than Valentech.
  • Alexion / AstraZeneca Rare Disease: Global leader in rare disease therapeutics (now part of AstraZeneca), commercializing treatments across haematology, nephrology, neurology, and metabolic rare diseases. Comparable in therapeutic focus areas where Valentech operates and in expanding access to LatAm via local partnerships.
  • Sanofi Genzyme (Rare Diseases): Global rare disease franchise (formerly Genzyme) commercializing therapies for rare and specialty conditions with established LatAm operations. Overlaps with Valentech on therapeutic areas such as rare metabolic, hematology, and neuropediatric conditions, but at a much larger scale.

Direct peers

  • Megalabs: Latin American pharmaceutical company with presence in 18+ countries covering branded generics, specialty, and rare disease products. Comparable as a multi-country LatAm commercialization partner for global pharma, with overlap in therapeutic categories such as gastro/hepato and endocrinology.
  • Biopas: Latin American specialty pharmaceutical company focused on rare diseases, specialty therapies, and biologics across multiple LatAm countries. Operates a very similar licensing, registration, importation, and commercialization model with global pharma partners, making it the closest functional peer to Valentech.
  • Knight Therapeutics (formerly Grupo Biotoscana / GBT Pharma): Specialty pharmaceutical distributor headquartered in LatAm (acquired by Knight Therapeutics), commercializing innovative therapies including rare disease products across the region. Highly comparable model of licensing and distributing partner pharma products across multiple LatAm markets.

Regional players

  • Raffo Laboratorios: Argentine pharmaceutical company with branded specialty, oncology, and rare disease products distributed across several LatAm countries. Comparable regional specialty pharmaceutical distributor with overlapping therapeutic categories, though headquartered and primarily operating in the Southern Cone.
  • Hypera Pharma: Largest Brazilian pharmaceutical company by market cap, with branded prescription, specialty, and consumer health products across LatAm. Comparable as a scaled LatAm pharmaceutical commercialization platform, though primarily Brazil-focused rather than Andean-region focused like Valentech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Valentech social profiles

Digital presence

Valentech compliance and trust

Trust signal

Compliance5 records

Valentech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valentech leadership team

Management profile

Number of profiles

Valentech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valentech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valentech

What does Valentech do?

Valentech Pharma is a pharmaceutical licensing, import, and commercialization company that registers, imports, and distributes innovative therapies for rare and orphan diseases in Colombia, Ecuador, Peru, and Panama. It partners with international pharmaceutical companies to bring high-specialty treatments to Latin America in therapeutic areas including rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics.

Is Valentech a public or private company?

Valentech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Valentech founded?

Valentech was founded in 2011. It employs 51 to 100 people.

Where is Valentech based?

Valentech is headquartered in Bogotá, Colombia, in the Latin America region.

How does Valentech make money?

One revenue line is on record: pharmaceutical Licensing and Distribution.

Who are Valentech's main competitors?

Broad incumbents on record are Eurofarma, Recordati Rare Diseases, Swedish Orphan Biovitrum (Sobi), Alexion / AstraZeneca Rare Disease and Sanofi Genzyme (Rare Diseases). Direct peers are Megalabs, Biopas and Knight Therapeutics (formerly Grupo Biotoscana / GBT Pharma). Regional players are Raffo Laboratorios and Hypera Pharma.

Does Valentech have an API?

No public API is recorded for Valentech.

What industry is Valentech in?

Valentech's product category is Specialty Pharmaceutical Distribution. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution. Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals